Klothea Bio Secures Funding from Longevitytech.fund as a lead investor to Pioneer Breakthrough Treatments for Metabolic Syndrome and several Aging-Associated DiseasesMIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Advantage Therapeutics Inc., a leader in developing therapies targeting age-related diseases, announced today the formation of its new subsidiary, Klothea Bio, Inc., which will focus exclusively on the research and development of Klotho-based therapies to prevent and treat various age-assoc

- Phase 1 study and Investigator Initiated Trial evaluating KL003 for patients with beta thalassemia demonstrated an encouraging efficacy signal and favorable safety profile – - Manufacturing costs for KL003 are significantly reduced compared to currently approved gene therapies - - Phase 2 pivotal study for KL003 in beta thalassemia expected to start in 2025 - Nov. 25, 2024 -- Kanglin Biotechnology (Hangzhou) Co., Ltd, an innovative biotech company developing the next generation of gene thera

Nov. 21, 2024 -- DANNCE.AI raised $2.6 million in pre-seed funding led by LDV Capital, following initial investment from Glasswing Ventures, with participation from The Leo Lion Company, Duke Capital Partners, and Merck Digital Sciences Studio. DANNCE.AI is bringing to market DANNCE, a novel phenotyping platform to digitize the clinical assessments used by doctors and therapeutic developers to quantify movement. DANNCE is a new approach to the clinical exam that ingests videos of patients and a

Nov. 11, 2024 -- AdipoPharma, a biotech company headquartered in France with offices in the US and Belgium developing a novel and promising Type 2 diabetes drug, announced today that it has successfully secured the funding needed to begin Phase 1 clinical trials. The company is slated to begin clinical trials in the U.S. in mid-2025. This crucial funding will enable AdipoPharma to accelerate its clinical development, marking a major milestone in the journey toward bringing a first-in-class com

Oct. 29, 2024 -- Pathos AI, a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, today announced the closing of an oversubscribed $62M Series C funding round. The Series C financing round was led by New Enterprise Associates (NEA) with participation from Revolution Growth and other existing insiders. This new capital infusion will enable Pathos to expand its team of world-class scientists and engineers, accelerate the development of

Oct. 22, 2024 (GLOBE NEWSWIRE) -- RespiriNTM Programme allows BioVersys’ NTM project to access up to €2 million of non-dilutive funding BioVersys taps into key expertise of the established RespiriNTM consortium members and will lead development of its candidates through preclinical and clinical studies BioVersys’ NTM candidates are derived from the company’s proprietary Ansamycin Chemistry platform and are being developed to address difficult-to-treat Mycobacterium avium complex (MAC) and Myco

-- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60 -- Oct. 21, 2024 -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Cardiopulmonary and Neurodegenerative disease through Abelson Tyrosine Kinase inhibition, tod

€451M Revolving Credit Facility refinanced with a maturity extended to February 2029 Issuance of a €200M Perpetual Deeply Subordinated Hybrid Bond subscribed by Sanofi €54M product capacity reservation for five products and further amendments to the global Manufacturing and Supply Agreement (MSA) agreed with Sanofi “The completion of the financing is an instrumental step in the execution of EUROAPI’s strategic roadmap” said Ludwig de Mot, Chief Executive Officer. “Combined with further developm

Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executed Development work is based on ModeX proprietary MSTAR technology that incorporates multiple antibody binding sites into a single molecule Oct. 07, 2024 -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, announces it has been awarded $35 million of additional funding under an existing contract

Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic One of the largest private Italian Biotech company financings to date Financing co-led by Sofinnova Partners, XGEN Venture and CDP Venture Capital forming a strong syndicate with Indaco SGR Funds dedicated to advancing off-the-shelf pediatric gene therapy for Methylmalonic Acidemia (MMA) into the clinic, and to bolstering the Company’s gene therapy pipeline 25 Sep